



PRESS RELEASE

Russian Regulatory Authority grants Pierrel S.p.A the Authorization to register its dental anesthetic drug “Pierrel Articaine”

Milan, 11 June 2010 – **Pierrel S.p.A.**, the global pharmaceutical service provider, announces that it has obtained the authorization by the **Russian Regulatory Authority** to register its drug **“Pierrel Articaine”** (dental anesthetic).

This authorization will allow Pierrel Group to sell “Pierrel Articaine” in the Russian fast growing market and whose sales registered in 2009 for injectable local anesthetics sector were about 50 million of drug cartridges.

“Pierrel Articaine” has an unique formulation with a lower epinephrine contents, stable pH values and significant longer expiration date. These significant advantages are made possible only through the adoption of advanced asepsis manufacturing technologies.

“We are proud to gain this important achievement – comments **Luigi Visani, Company CEO**. Following the approval obtained already in countries like Italy and Canada and more recently by FDA in USA last March - our Group is now able to penetrate into a new market, with significant growth prospects such as Russia . This is a clear proof of Pierrel Group capabilities and competences”.

Pierrel S.p.A.

Pierrel S.p.A., a global provider to the pharmaceutical and life science industries, specialized in Research and development (Contract Research) and production (Contract Manufacturing) of drug products, is listed in the Italian Stock Exchange market. The Pierrel Group enjoys more than 50 years experience in the pharmaceutical sector and is one of the main European manufacturers of dental anaesthetic drug products. The CRO division, Pierrel Research, with about 20 subsidiaries operates both in Europe and USA, providing consultancies and full services for research and development of new molecules and drug products. The manufacturing plant in Capua, near Naples (Italy), has been authorized by FDA for the production of sterile small volumes parenteral drugs. Pierrel S.p.A Corporate Office is located in Milan, Italy.



For further information:

Pierrel S.p.A.

Investor Relator

Dott. Aurelio Matrone

Email: investor.relations@pierrelgroup.com

tel. +39 02 2413491

fax +39 02 24134201

Image Building

Simona Raffaelli, Valentina Burlando

Tel. 02/8901.1300

E-mail: pierrel@imagebuilding.it